Search Share Prices
ImmuPharma anticipating latest Lupuzor test results in April
Specialist drug discovery and development company ImmuPharma announced on Friday that it has been informed by Simbec-Orion, the contract research organisation conducting its 'Lupuzor' pivotal Phase III trial study, that 'database lock' was expected on 6 April, with top line results announced by mid-April.
The AIM-traded firm said Lupuzor is its lead programme for the potential breakthrough compound for lupus - a life threatening autoimmune disease.
"With the continued robust safety record of Lupuzor achieved over this trial, we look forward with confidence to reporting top line results in the near future," said ImmuPharma chairman Tim McCarthy.